Insmed ARIKAYCE Investor Presentation

Insmed is a biopharmaceutical company focused on commercializing ARIKAYCE, an inhaled antibiotic for treating nontuberculous mycobacteria (NTM) lung disease, with ongoing clinical development of brensocatib and TPIP candidates. The presentation outlines risks and uncertainties related to product commercialization, regulatory approval, manufacturing, and market acceptance.